Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status Prescription; Discontinued
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 68071-4215; 23155-019; 70518-1829; 50090-0086; 49964-0018; 43353-495; 63629-5688; 70518-0185; 51927-0054; 51927-0081; 0591-0796; 0013-0101; 59762-0104; 38779-0176; 0013-0102; 50268-730; 59116-0632; 62705-0222; 62991-2704; 57294-021; 59116-0631; 71610-577; 59762-5000; 59116-0633; 59116-0630; 62135-960; 51552-1044; 50090-2013; 49452-7523; 68022-7065; 70518-2342
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Leukopenias NECCytochrome P450 1A2P05177Not Available11600468; 11856081; 11600469
VasculitisMyeloperoxidaseP05164T234717913504; 7913503; 8102951; 7914458; 8624621; 7869327; 7835022; 8095074; 8624617
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.0030.005526%Not Available
Paraesthesia17.02.06.005--
Pemphigoid23.03.01.004; 10.04.02.0020.001382%Not Available
Pericardial effusion02.06.01.0020.004145%
Pericarditis02.06.02.001--
Periorbital oedema06.08.03.017; 23.04.01.002; 10.01.05.010--
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.001382%Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.0040.002763%
Photophobia17.17.02.006; 06.01.01.0040.001382%
Photosensitivity reaction23.03.09.0030.002072%
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.0020.006217%
Pleurisy22.05.01.0010.002072%Not Available
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pneumonitis22.01.01.0060.002763%
Polyarteritis nodosa24.05.02.011; 20.01.02.004; 15.06.01.003; 10.02.02.001--Not Available
Polyneuropathy17.09.03.0120.001382%Not Available
Polyuria20.02.03.002--Not Available
Productive cough22.02.03.0050.001382%
Proteinuria20.02.01.011--
Pruritus23.03.12.0010.015887%
Pseudomembranous colitis11.02.02.002; 07.19.01.003--Not Available
Psoriasis10.02.01.036; 23.03.14.002--Not Available
Psoriatic arthropathy23.03.14.005; 15.01.10.001; 10.02.01.0310.002072%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 15 Pages